HGF mimetic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Stored desiccated before use |
| Recommended storage | -20 °C | Protect from light and moisture |
| Common stock solvent | Dimethyl sulfoxide | Aqueous solubility may be limited |
| Purity method | Reverse-phase HPLC | Reports percent purity and impurities |
| Identity method | Mass spectrometry | Confirms molecular mass |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
=== Phase 2 === 7-Oxoprasterone (7-keto-DHEA; HBL-9001; HL-9001; At-Ease) – undefined mechanism of action (immunomodulator) [4] [5] Amdiglurax (ALTO-100; NSI-189) – unknown mechanism of action (hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator) [6] [7] BI-1358894 – transient receptor potential cation channel TRPC4 and TRPC5 inhibitor [8] Cannabidiol (A-1002-N5S; CBD; Nantheia™) – cannabinoid, various actions [9] CORT-108297 (ADS-108297) – glucocorticoid receptor antagonist [10] Dronabinol (BX-1) – cannabinoid CB1 and CB2 receptor agonist [11] Iloperidone (Fanapt; Fanaptum; Fiapta; HP-873; ILO-522; VYV-683; Zomaril) – atypical antipsychotic (non-selective monoamine receptor modulator) [12] Ketamine intranasal (Ereska; PMI-100; PMI-150; SLS-002; TUR-002) – NMDA receptor antagonist and dissociative hallucinogen [13] Lithium cocrystal (AL-001; LiProSal; lithium salicylate/L-proline cocrystal) – undefined mechanism of action and mood stabilizer (improved formulation of lithium) [14] Methylone (MDMC; TSND-201) – serotonin–norepinephrine–dopamine releasing agent and entactogen Midomafetamine/citalopram (MDMA/citalopram) – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen followed by a selective serotonin reuptake inhibitor Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [15] Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and psychedelic hallucinogen [16] Soclenicant (BNC-210; IW-2143) – α7-nicotinic acetylcholine receptor antagonist [17] SRX-246 (API-246) – vasopressin V1A receptor antagonist [18] Xenon (NBTX-001) – NMDA receptor antagonist [19]
"I poured the wine into the chalice our church had given me. In the one-sixth gravity of the moon, the wine curled slowly and gracefully up the side of the cup. It was interesting to think that the very first liquid ever poured on the moon, and the first food eaten there, were communion elements." —Buzz Aldrin Aldrin received the Eucharist in the same hour that his local church did on that Sunday Sabbath and he later stated that "I sensed especially strongly my unity with our church back home, and with the Church everywhere".
Etacrynic acid (INN) or ethacrynic acid (USAN), trade name Edecrin, is a loop diuretic used to treat high blood pressure and the swelling caused by diseases like congestive heart failure, liver failure, and kidney failure. A disadvantage with ethacrynic acid, compared to the other loop diuretic drugs such as furosemide, is that it has a significantly steep dose-response curve. This means the drug's dosing is very important as small variance in dose can cause a significant difference in the biological response. Unlike the other loop diuretics, etacrynic acid is not a sulfonamide and may thus be used in individuals with sulfa allergies in whom the sulfonamide loop diuretics would be contraindicated.
The discipline of plant ecology was pioneered in the late 19th century by botanists such as Eugenius Warming, who produced the hypothesis that plants form communities, and his mentor and successor Christen C. Raunkiær whose system for describing plant life forms is still in use today. The concept that the composition of plant communities such as temperate broadleaf forest changes by a process of ecological succession was developed by Henry Chandler Cowles, Arthur Tansley and Frederic Clements. Clements is credited with the idea of climax vegetation as the most complex vegetation that an environment can support and Tansley introduced the concept of ecosystems to biology. Building on the extensive earlier work of Alphonse de Candolle, Nikolai Vavilov (1887–1943) produced accounts of the biogeography, centres of origin, and evolutionary history of economic plants. Particularly since the mid-1960s there have been advances in understanding of the physics of plant physiological processes such as transpiration (the transport of water within plant tissues), the temperature dependence of rates of water evaporation from the leaf surface and the molecular diffusion of water vapour and carbon dioxide through stomatal apertures. These developments, coupled with new methods for measuring the size of stomatal apertures, and the rate of photosynthesis have enabled a precise description of the rates of gas exchange between plants and the atmosphere.
Sources: en.wikipedia.org
=== Surgery === Surgical intervention is indicated in patients with symptomatic exposed bone with fistula formation and one or more of the following: exposed and necrotic bone extending beyond the alveolar bone resulting in pathological fracture; extra-oral fistula; oral antral communication or osteolysis extending from the inferior border of the mandible or the sinus floor. Surgical management involves necrotic bone resection, removal of loose sequestra of necrotic bone and reconstructive surgery. The objective of surgical management is to eliminate areas of exposed bone to prevent the risk of further inflammation and infection. The amount of surgical debridement required remains controversial.
During the mid-19th century, attempts were made to ship agricultural products by rail. As early as 1842, the Western Railroad of Massachusetts was reported in the June 15 edition of the Boston Traveler to be experimenting with innovative freight car designs capable of carrying all types of perishable goods without spoilage. The first refrigerated boxcar entered service in June 1851, on the Northern Railroad (New York) (or NRNY, which later became part of the Rutland Railroad). This "icebox on wheels" was a limited success since it was only functional in cold weather. That same year, the Ogdensburg and Lake Champlain Railroad (O&LC) began shipping butter to Boston in purpose-built freight cars, using ice for cooling.
Likewise, polymeric residue can contribute to a similar decrease in the thermal conductivity of suspended graphene to approximately 500 – 600 W⋅m−1⋅K−1 for bilayer graphene. Isotopic composition, specifically the ratio of 12C to 13C, significantly affects graphene's thermal conductivity. Isotopically pure 12C graphene exhibits higher thermal conductivity than either a 50:50 isotope ratio or the naturally occurring 99:1 ratio. It can be shown by using the Wiedemann–Franz law, that the thermal conduction is phonon-dominated. However, for a gated graphene strip, an applied gate bias causing a Fermi energy shift much larger than kBT can cause the electronic contribution to increase and dominate over the phonon contribution at low temperatures. The ballistic thermal conductance of graphene is isotropic. Graphite, a 3D counterpart to graphene, exhibits a basal plane thermal conductivity exceeding 1000 W⋅m−1⋅K−1 (similar to diamond), In graphite, the c-axis (out of plane) thermal conductivity is over a factor of ~100 smaller due to the weak binding forces between basal planes as well as the larger lattice spacing. In addition, the ballistic thermal conductance of graphene is shown to give the lower limit of the ballistic thermal conductance, per unit circumference, length of carbon nanotubes. Graphene's thermal conductivity is influenced by its three acoustic phonon modes: two linear dispersion relation dispersion relation in-plane modes (LA, TA) and one quadratic dispersion relation out-of-plane mode (ZA).
Sources: en.wikipedia.org
Once the ligand interacting with the target macromolecule is identified, drug candidates can be designed and optimized based on the structure-activity relationship. Nowadays, artificial intelligence is employed in drug design to predict drug-protein interactions, drug activity, the 3D configuration of proteins, etc.
Altogether, total employment in 2017 amounted to 2,919,000 people according to Statistics Denmark. The share of employees leaving jobs every year (for a new job, retirement or unemployment) in the private sector is around 30% – a level also observed in the U.K. and U.S.- but much higher than in continental Europe, where the corresponding figure is around 10%, and in Sweden. This attrition can be very costly, with new and old employees requiring half a year to return to old productivity levels, but with attrition bringing the number of people that have to be fired down.
Countercurrent chromatography (CCC, also counter-current chromatography) is a form of liquid–liquid chromatography that uses a liquid stationary phase that is held in place by inertia of the molecules composing the stationary phase accelerating toward the center of a centrifuge due to centripetal force and is used to separate, identify, and quantify the chemical components of a mixture. In its broadest sense, countercurrent chromatography encompasses a collection of related liquid chromatography techniques that employ two immiscible liquid phases without a solid support. The two liquid phases come in contact with each other as at least one phase is pumped through a column, a hollow tube or a series of chambers connected with channels, which contains both phases. The resulting dynamic mixing and settling action allows the components to be separated by their respective solubilities in the two phases. A wide variety of two-phase solvent systems consisting of at least two immiscible liquids may be employed to provide the proper selectivity for the desired separation. Some types of countercurrent chromatography, such as dual flow CCC, feature a true countercurrent process where the two immiscible phases flow past each other and exit at opposite ends of the column. More often, however, one liquid acts as the stationary phase and is retained in the column while the mobile phase is pumped through it.
The Bouyakhrichan organisation was a criminal organisation led by Samir Bouyakhrichan (also known as Scarface), who was a billionaire entrepreneur and drug lord. Samir was specialised in large scale drug trafficking which he gained through collaborations with Colombian cartels. His organisation also operated in Spain, where it controlled parts of the Costa del Sol region. Bouyakhrichan was known for using his fortune to organise extravagant private parties by renting luxurious rooms in places like Dubai and Amsterdam, which included champagne, cocaine, and a lot of women and escorts. The guests were mostly Moroccan and British. One of these private parties was that of 30 June 2012, at the Apollo Hotel in Amsterdam. During this evening, many major drug lords were present, alongside the famous Dutch singer Gordon. Samir Bouyakhrichan was a known rival of the Taghi organisation, and he was also considered to be a rival of "Noffel". On 29 August 2014, at the age of 34, Samir was assassinated in southern Spain by 2 contract killers. The assassination was allegedly orchestrated by "Noffel"'s organisation. After his death, his organisation was taken over by his brother Karim Bouyakhrichan (also known as Taxi). According to the Dutch authorities, Taghi and his associate Rico "El Rico" Eduardo Riquelme Vega were "hunting" for Karim to dismantle the Bouyakhrichan organisation.
Sources: en.wikipedia.org
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.
Mass spectrometry is commonly used to confirm molecular mass, while reverse-phase HPLC assesses purity. Some laboratories also use nuclear magnetic resonance for structural verification. These methods are standard for research peptides.
Aqueous solubility can be limited and varies by batch and salt form. Dimethyl sulfoxide is often used for stock solutions. Supplier documentation or a solubility test can clarify behavior for a given lot.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.